Six patients (50%) were evaluable for clinical efficacy, with 3 out of 6 partial responses, which represents a substantial improvement vs initial phase I clinical trial (1 in 145 patients) Highlights Vivia Biotech is a key enabler for drug and biomarker discovery & development
Hyperhydration and glycerol: thermoregulatory effects during exercise in hot climates
These are the GLP-1 and GIP receptor agonists: semaglutide (Wegovy) and tirzepatide (Mounjaro), both of which are MHRA-approved and available on prescription in the UK
7,8 Many case series, however, diagnosed AIG solely based on serological markers such as IFAs or PCAs, pepsinogen levels or gastrin-17, without confirmatory biopsy
Side effects and injection-site reactions: the real incidence data Aggregated side effect reports from 1,200+ patient reviews and compounding pharmacy adverse-event logs: Injection-site soreness is the dominant complaint